000304605 001__ 304605
000304605 005__ 20250919115037.0
000304605 0247_ $$2doi$$a10.1016/j.esmoop.2025.105812
000304605 0247_ $$2pmid$$apmid:40961643
000304605 037__ $$aDKFZ-2025-01924
000304605 041__ $$aEnglish
000304605 082__ $$a610
000304605 1001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b0$$eLast author$$udkfz
000304605 245__ $$aLetter to the editor re: CDX2 expression as a predictive and prognostic biomarker of 5-fluorouracil response in cancer of unknown primary.
000304605 260__ $$a[London]$$bElsevier$$c2025
000304605 3367_ $$2DRIVER$$aarticle
000304605 3367_ $$2DataCite$$aOutput Types/Journal article
000304605 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1758201396_22717$$xLetter
000304605 3367_ $$2BibTeX$$aARTICLE
000304605 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000304605 3367_ $$00$$2EndNote$$aJournal Article
000304605 500__ $$a#LA:A360#
000304605 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000304605 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000304605 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2025.105812$$gVol. 10, no. 10, p. 105812 -$$n10$$p105812$$tESMO open$$v10$$x2059-7029$$y2025
000304605 909CO $$ooai:inrepo02.dkfz.de:304605$$pVDB
000304605 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000304605 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000304605 9141_ $$y2025
000304605 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000304605 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000304605 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000304605 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-30
000304605 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-30
000304605 9202_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000304605 9201_ $$0I:(DE-He78)A360-20160331$$kA360$$lKKE Mol. Hämatologie/Onkologie$$x0
000304605 980__ $$ajournal
000304605 980__ $$aVDB
000304605 980__ $$aI:(DE-He78)A360-20160331
000304605 980__ $$aUNRESTRICTED